This year, you made the difference.
In a year filled with gridlock for biomedical research and public health, your voice kept ME/CFS on the agenda. You showed up, spoke out, and pushed for action – and because of that, we protected programs, advanced science, and built real momentum for change.
Here’s a look at what you helped make possible in 2025:
You Put ME/CFS Front and Center in Congress
You led meetings, shared your stories, and pushed lawmakers to act on our community’s top federal priorities. Here’s where things stand:
Restore Department of Defense Congressionally Directed Medical Research Programs (CDMRP) Funding
Status: Thanks to your advocacy, ME/CFS remains an eligible topic within the Peer-Reviewed Medical Research Program (PRMRP) at the Department of Defense.
For the broader CDMRP funding, we are continuing to participate in a cross-disease coalition effort through the Defense Health Research Coalition, pushing to reverse this year’s 57% funding cut. The next key moment for updates will be the appropriations deadline at the end of January
Protect and Expand the CDC’s ME/CFS Program
Status: The Senate version of the appropriations language fully funds the program; the House version does not. We’re continuing to push for full inclusion in the final reconciled bill, with an eye on the January deadline.
Fund the NIH ME/CFS Research Roadmap
Status: This remains an active ask. NIH supports the roadmap, but without congressional appropriations it cannot be implemented. The fight continues.
You Helped Shift the Global Conversation
This month, Germany announced a €500 million investment in post-viral illnesses like Long COVID and ME/CFS – one of the largest public commitments to these conditions to date.
Why it matters: Governments are starting to wake up to the economic and workforce impact of infection-associated chronic illnesses. With your continued advocacy, the U.S. can – and must – do the same.
RECOVER Trials Progress Continues
Solve was part of the original push to get the $1.2 billion in funding for the NIH’s RECOVER program, and in 2025 the program focused on designing trials for:
•Low-dose naltrexone (LDN)
•GLP-1 receptor agonists (e.g., tirzepatide)
•Baricitinib (a JAK inhibitor)
•Stellate ganglion nerve blocks
Why it matters: These trials reflect the real-world needs and experiences of patients — and show that your advocacy is helping shape national research priorities.
Because of your actions, ME/CFS stayed visible – in policy rooms, research labs, and global headlines.
We’re proud to stand with you. Thank you for everything you’ve contributed to the community throughout 2025.